HIGHLIGHTS
- who: Yuping Yin from the China Qingdao University, China have published the Article: Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial, in the Journal: (JOURNAL) of 20/05/2022
- what: More importantly, the authors examined the expression of immune cytokine and a variety of immune cells in enrolled patients; to the knowledge , this is the Frontiers in Oncology frontiersin.org 10.3389/fonc.2022.959295 A B (A) Maximum tumor shrinkage in depth of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.